News

Neovacs has initiated Phase IIa clinical study of its TNFa Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFa monoclonal antibody and who

Galapagos has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK). For entering the clinic with candidate drug GLPG0555,

Rib-X Pharmaceuticals (Rib-X) has entered into a further license agreement with Yale University in the area of ribosome and antibiotic structure and function. Under the agreement, Rib-X is

ImmunoGen has presented positive initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to

Cevec Pharmaceuticals (Cevec) and Inno Biologics have entered into a strategic license agreement. The license enables Inno Biologics to offer the full potential of production of their diagnostic

Roche has reported that the pivotal phase III study, CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with MabThera/Rituxan (rituximab),

Bayer’s consumer care division has begun a voluntary recall of a single product lot of the combination package of Alka-Seltzer Plus day and night cold formula liquid gels,

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has received clearance from the FDA to utilise its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec

MeadWestvaco (MWV) has appointed Peter Durette as the new chief strategy officer and vice president of the company. In this new role, Mr. Durette is expected to oversee